nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—AR—polycystic ovary syndrome	0.875	1	CbGaD
Bicalutamide—Enzalutamide—AR—polycystic ovary syndrome	0.00518	1	CrCbGaD
Bicalutamide—Tooth abscess—Metformin—polycystic ovary syndrome	0.00462	0.0907	CcSEcCtD
Bicalutamide—CYP2C19—urine—polycystic ovary syndrome	0.00456	0.175	CbGeAlD
Bicalutamide—CYP2C9—urine—polycystic ovary syndrome	0.00354	0.135	CbGeAlD
Bicalutamide—CYP3A4—urine—polycystic ovary syndrome	0.0027	0.103	CbGeAlD
Bicalutamide—CYP2D6—urine—polycystic ovary syndrome	0.00265	0.102	CbGeAlD
Bicalutamide—Blood disorder—Metformin—polycystic ovary syndrome	0.00231	0.0454	CcSEcCtD
Bicalutamide—Neuropathy—Metformin—polycystic ovary syndrome	0.00181	0.0356	CcSEcCtD
Bicalutamide—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00144	0.0282	CcSEcCtD
Bicalutamide—AR—adrenal cortex—polycystic ovary syndrome	0.0013	0.0499	CbGeAlD
Bicalutamide—Dehydration—Metformin—polycystic ovary syndrome	0.0013	0.0256	CcSEcCtD
Bicalutamide—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00129	0.0254	CcSEcCtD
Bicalutamide—Breast disorder—Metformin—polycystic ovary syndrome	0.00127	0.0249	CcSEcCtD
Bicalutamide—Influenza—Metformin—polycystic ovary syndrome	0.00121	0.0238	CcSEcCtD
Bicalutamide—Angina pectoris—Metformin—polycystic ovary syndrome	0.00118	0.0232	CcSEcCtD
Bicalutamide—AR—endometrium—polycystic ovary syndrome	0.00116	0.0446	CbGeAlD
Bicalutamide—Neutropenia—Metformin—polycystic ovary syndrome	0.00113	0.0222	CcSEcCtD
Bicalutamide—AR—uterus—polycystic ovary syndrome	0.00107	0.0411	CbGeAlD
Bicalutamide—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00106	0.0208	CcSEcCtD
Bicalutamide—AR—pituitary gland—polycystic ovary syndrome	0.00105	0.0404	CbGeAlD
Bicalutamide—AR—adipose tissue—polycystic ovary syndrome	0.00105	0.0402	CbGeAlD
Bicalutamide—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00102	0.02	CcSEcCtD
Bicalutamide—Bradycardia—Metformin—polycystic ovary syndrome	0.000987	0.0194	CcSEcCtD
Bicalutamide—Rhinitis—Metformin—polycystic ovary syndrome	0.000972	0.0191	CcSEcCtD
Bicalutamide—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000955	0.0187	CcSEcCtD
Bicalutamide—AR—adrenal gland—polycystic ovary syndrome	0.000941	0.036	CbGeAlD
Bicalutamide—Cardiac disorder—Metformin—polycystic ovary syndrome	0.0009	0.0177	CcSEcCtD
Bicalutamide—Angiopathy—Metformin—polycystic ovary syndrome	0.000879	0.0173	CcSEcCtD
Bicalutamide—AR—female gonad—polycystic ovary syndrome	0.000878	0.0336	CbGeAlD
Bicalutamide—Immune system disorder—Metformin—polycystic ovary syndrome	0.000875	0.0172	CcSEcCtD
Bicalutamide—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000874	0.0171	CcSEcCtD
Bicalutamide—AR—vagina—polycystic ovary syndrome	0.000872	0.0334	CbGeAlD
Bicalutamide—Chills—Metformin—polycystic ovary syndrome	0.00087	0.0171	CcSEcCtD
Bicalutamide—Malnutrition—Metformin—polycystic ovary syndrome	0.000844	0.0166	CcSEcCtD
Bicalutamide—Flatulence—Metformin—polycystic ovary syndrome	0.000831	0.0163	CcSEcCtD
Bicalutamide—AR—endocrine gland—polycystic ovary syndrome	0.000816	0.0313	CbGeAlD
Bicalutamide—Muscle spasms—Metformin—polycystic ovary syndrome	0.000811	0.0159	CcSEcCtD
Bicalutamide—CYP2C19—vagina—polycystic ovary syndrome	0.000808	0.031	CbGeAlD
Bicalutamide—Syncope—Metformin—polycystic ovary syndrome	0.000757	0.0149	CcSEcCtD
Bicalutamide—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000756	0.029	CbGeAlD
Bicalutamide—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000742	0.0146	CcSEcCtD
Bicalutamide—Hypertension—Metformin—polycystic ovary syndrome	0.000728	0.0143	CcSEcCtD
Bicalutamide—Chest pain—Metformin—polycystic ovary syndrome	0.000718	0.0141	CcSEcCtD
Bicalutamide—Myalgia—Metformin—polycystic ovary syndrome	0.000718	0.0141	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000713	0.014	CcSEcCtD
Bicalutamide—Oedema—Metformin—polycystic ovary syndrome	0.000689	0.0135	CcSEcCtD
Bicalutamide—Infection—Metformin—polycystic ovary syndrome	0.000684	0.0134	CcSEcCtD
Bicalutamide—Shock—Metformin—polycystic ovary syndrome	0.000677	0.0133	CcSEcCtD
Bicalutamide—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000675	0.0133	CcSEcCtD
Bicalutamide—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000674	0.0132	CcSEcCtD
Bicalutamide—Skin disorder—Metformin—polycystic ovary syndrome	0.000669	0.0131	CcSEcCtD
Bicalutamide—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000666	0.0131	CcSEcCtD
Bicalutamide—Anorexia—Metformin—polycystic ovary syndrome	0.000656	0.0129	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000627	0.0123	CcSEcCtD
Bicalutamide—Paraesthesia—Metformin—polycystic ovary syndrome	0.000618	0.0121	CcSEcCtD
Bicalutamide—Dyspnoea—Metformin—polycystic ovary syndrome	0.000614	0.0121	CcSEcCtD
Bicalutamide—Somnolence—Metformin—polycystic ovary syndrome	0.000612	0.012	CcSEcCtD
Bicalutamide—Dyspepsia—Metformin—polycystic ovary syndrome	0.000606	0.0119	CcSEcCtD
Bicalutamide—Decreased appetite—Metformin—polycystic ovary syndrome	0.000599	0.0118	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000594	0.0117	CcSEcCtD
Bicalutamide—Fatigue—Metformin—polycystic ovary syndrome	0.000594	0.0117	CcSEcCtD
Bicalutamide—Constipation—Metformin—polycystic ovary syndrome	0.000589	0.0116	CcSEcCtD
Bicalutamide—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000586	0.0225	CbGeAlD
Bicalutamide—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000567	0.0111	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000563	0.0111	CcSEcCtD
Bicalutamide—Urticaria—Metformin—polycystic ovary syndrome	0.000547	0.0107	CcSEcCtD
Bicalutamide—Abdominal pain—Metformin—polycystic ovary syndrome	0.000544	0.0107	CcSEcCtD
Bicalutamide—Asthenia—Metformin—polycystic ovary syndrome	0.000494	0.0097	CcSEcCtD
Bicalutamide—Pruritus—Metformin—polycystic ovary syndrome	0.000487	0.00956	CcSEcCtD
Bicalutamide—CYP2D6—female gonad—polycystic ovary syndrome	0.000473	0.0181	CbGeAlD
Bicalutamide—Diarrhoea—Metformin—polycystic ovary syndrome	0.000471	0.00925	CcSEcCtD
Bicalutamide—Dizziness—Metformin—polycystic ovary syndrome	0.000455	0.00894	CcSEcCtD
Bicalutamide—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000447	0.0171	CbGeAlD
Bicalutamide—CYP2D6—endocrine gland—polycystic ovary syndrome	0.00044	0.0169	CbGeAlD
Bicalutamide—Vomiting—Metformin—polycystic ovary syndrome	0.000438	0.0086	CcSEcCtD
Bicalutamide—Rash—Metformin—polycystic ovary syndrome	0.000434	0.00852	CcSEcCtD
Bicalutamide—Dermatitis—Metformin—polycystic ovary syndrome	0.000434	0.00852	CcSEcCtD
Bicalutamide—Headache—Metformin—polycystic ovary syndrome	0.000431	0.00847	CcSEcCtD
Bicalutamide—Nausea—Metformin—polycystic ovary syndrome	0.000409	0.00803	CcSEcCtD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	9.52e-05	0.0022	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	9.35e-05	0.00216	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—SULT2A1—polycystic ovary syndrome	9.23e-05	0.00213	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—SULT2A1—polycystic ovary syndrome	9.15e-05	0.00212	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	9.13e-05	0.00211	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	9.13e-05	0.00211	CbGpPWpGaD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	9.13e-05	0.00211	CbGpPWpGaD
Bicalutamide—CYP3A4—Tryptophan metabolism—CYP1A1—polycystic ovary syndrome	9.1e-05	0.0021	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	9.1e-05	0.0021	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	9.05e-05	0.00209	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	9.02e-05	0.00209	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	9.01e-05	0.00208	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—PGR—polycystic ovary syndrome	8.95e-05	0.00207	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP11A1—polycystic ovary syndrome	8.89e-05	0.00205	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BCL2—polycystic ovary syndrome	8.77e-05	0.00203	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	8.77e-05	0.00203	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	8.76e-05	0.00203	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	8.68e-05	0.00201	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	8.39e-05	0.00194	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	8.32e-05	0.00192	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	8.32e-05	0.00192	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	8.28e-05	0.00191	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP17A1—polycystic ovary syndrome	8.26e-05	0.00191	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP11A1—polycystic ovary syndrome	8.17e-05	0.00189	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	8.15e-05	0.00188	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP11A1—polycystic ovary syndrome	8.1e-05	0.00187	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	8.06e-05	0.00186	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	7.99e-05	0.00185	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	7.61e-05	0.00176	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP17A1—polycystic ovary syndrome	7.6e-05	0.00176	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	7.55e-05	0.00174	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP17A1—polycystic ovary syndrome	7.53e-05	0.00174	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	7.53e-05	0.00174	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	7.53e-05	0.00174	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	7.5e-05	0.00173	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	7.43e-05	0.00172	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	7.4e-05	0.00171	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	7.4e-05	0.00171	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	7.36e-05	0.0017	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—RPL37A—polycystic ovary syndrome	7.36e-05	0.0017	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	7.27e-05	0.00168	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	7.26e-05	0.00168	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	6.86e-05	0.00159	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	6.86e-05	0.00159	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	6.8e-05	0.00157	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	6.75e-05	0.00156	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—VEGFA—polycystic ovary syndrome	6.56e-05	0.00152	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP19A1—polycystic ovary syndrome	6.54e-05	0.00151	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	6.47e-05	0.00149	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	6.45e-05	0.00149	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	6.39e-05	0.00148	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	6.31e-05	0.00146	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—NCOR1—polycystic ovary syndrome	6.08e-05	0.00141	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—SULT2A1—polycystic ovary syndrome	6.03e-05	0.00139	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP19A1—polycystic ovary syndrome	6.01e-05	0.00139	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	5.98e-05	0.00138	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	5.97e-05	0.00138	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP19A1—polycystic ovary syndrome	5.96e-05	0.00138	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	5.95e-05	0.00138	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	5.93e-05	0.00137	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	5.88e-05	0.00136	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	5.75e-05	0.00133	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	5.7e-05	0.00132	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—NR3C1—polycystic ovary syndrome	5.63e-05	0.0013	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	5.49e-05	0.00127	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	5.45e-05	0.00126	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	5.44e-05	0.00126	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP11A1—polycystic ovary syndrome	5.34e-05	0.00124	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	5.27e-05	0.00122	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP1A1—polycystic ovary syndrome	5.27e-05	0.00122	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	5.2e-05	0.0012	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	5.2e-05	0.0012	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	4.98e-05	0.00115	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP17A1—polycystic ovary syndrome	4.97e-05	0.00115	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—YAP1—polycystic ovary syndrome	4.93e-05	0.00114	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	4.9e-05	0.00113	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	4.85e-05	0.00112	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP1A1—polycystic ovary syndrome	4.85e-05	0.00112	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP1A1—polycystic ovary syndrome	4.81e-05	0.00111	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	4.78e-05	0.00111	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	4.74e-05	0.0011	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NMNAT3—polycystic ovary syndrome	4.64e-05	0.00107	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	4.45e-05	0.00103	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	4.42e-05	0.00102	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	4.42e-05	0.00102	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	4.42e-05	0.00102	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—PPARG—polycystic ovary syndrome	4.36e-05	0.00101	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—TNRC6B—polycystic ovary syndrome	4.35e-05	0.00101	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	4.32e-05	0.000999	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PGR—polycystic ovary syndrome	4.31e-05	0.000996	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NMNAT3—polycystic ovary syndrome	4.26e-05	0.000986	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SUOX—polycystic ovary syndrome	4.24e-05	0.00098	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—LPCAT2—polycystic ovary syndrome	4.24e-05	0.00098	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NMNAT3—polycystic ovary syndrome	4.23e-05	0.000977	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	4.19e-05	0.000968	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	4.03e-05	0.000932	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ISYNA1—polycystic ovary syndrome	3.94e-05	0.000911	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	3.94e-05	0.000911	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	3.93e-05	0.000909	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—POMC—polycystic ovary syndrome	3.93e-05	0.000909	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—SERPINE1—polycystic ovary syndrome	3.93e-05	0.000908	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	3.9e-05	0.000902	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	3.9e-05	0.000902	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	3.88e-05	0.000897	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SUOX—polycystic ovary syndrome	3.87e-05	0.000894	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—LPCAT2—polycystic ovary syndrome	3.87e-05	0.000894	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	3.85e-05	0.000891	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	3.82e-05	0.000883	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	3.63e-05	0.000838	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	3.61e-05	0.000836	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	3.6e-05	0.000832	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ISYNA1—polycystic ovary syndrome	3.59e-05	0.000831	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—POMC—polycystic ovary syndrome	3.58e-05	0.000828	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	3.51e-05	0.000812	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	3.41e-05	0.000789	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKR1C2—polycystic ovary syndrome	3.35e-05	0.000775	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TEAD2—polycystic ovary syndrome	3.35e-05	0.000775	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	3.28e-05	0.000758	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	3.22e-05	0.000745	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	3.17e-05	0.000734	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	3.17e-05	0.000733	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	3.13e-05	0.000723	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	3.11e-05	0.000719	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	3.08e-05	0.000713	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	3.08e-05	0.000713	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	3.06e-05	0.000707	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	3.06e-05	0.000707	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	2.94e-05	0.000679	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NCOR1—polycystic ovary syndrome	2.93e-05	0.000677	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	2.89e-05	0.000669	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PNPLA2—polycystic ovary syndrome	2.81e-05	0.000649	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	2.79e-05	0.000645	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NR3C1—polycystic ovary syndrome	2.71e-05	0.000626	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SRD5A1—polycystic ovary syndrome	2.66e-05	0.000616	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	2.58e-05	0.000597	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	2.56e-05	0.000592	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	2.55e-05	0.00059	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	2.55e-05	0.00059	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—STAR—polycystic ovary syndrome	2.54e-05	0.000587	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.51e-05	0.00058	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	2.45e-05	0.000566	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	2.43e-05	0.000561	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	2.37e-05	0.000548	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	2.36e-05	0.000546	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	2.34e-05	0.00054	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	2.32e-05	0.000535	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.29e-05	0.000529	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—HMMR—polycystic ovary syndrome	2.26e-05	0.000523	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—HSD3B1—polycystic ovary syndrome	2.16e-05	0.000499	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.14e-05	0.000494	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PPARG—polycystic ovary syndrome	2.1e-05	0.000485	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	2.08e-05	0.000481	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	2.06e-05	0.000477	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.02e-05	0.000468	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	2.02e-05	0.000466	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	2.02e-05	0.000466	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	1.99e-05	0.000459	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	1.97e-05	0.000455	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	1.97e-05	0.000455	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.95e-05	0.00045	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	1.93e-05	0.000445	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—SERPINE1—polycystic ovary syndrome	1.89e-05	0.000437	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	1.86e-05	0.000431	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.85e-05	0.000427	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.81e-05	0.000419	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	1.8e-05	0.000415	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.77e-05	0.000409	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	1.76e-05	0.000406	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	1.72e-05	0.000397	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.71e-05	0.000396	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	1.7e-05	0.000393	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	1.69e-05	0.000391	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	1.66e-05	0.000384	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	1.6e-05	0.00037	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	1.6e-05	0.00037	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	1.58e-05	0.000365	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	1.56e-05	0.000362	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	1.54e-05	0.000356	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.53e-05	0.000354	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.53e-05	0.000353	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	1.53e-05	0.000353	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	1.52e-05	0.000351	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	1.52e-05	0.00035	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.51e-05	0.000349	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.47e-05	0.000341	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	1.46e-05	0.000338	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	1.44e-05	0.000332	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.42e-05	0.000327	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	1.41e-05	0.000327	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	1.4e-05	0.000324	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.4e-05	0.000323	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.4e-05	0.000323	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	1.39e-05	0.00032	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.38e-05	0.000318	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	1.36e-05	0.000315	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.32e-05	0.000305	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	1.31e-05	0.000303	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.3e-05	0.0003	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	1.3e-05	0.0003	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	1.29e-05	0.000298	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TH—polycystic ovary syndrome	1.22e-05	0.000283	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	1.19e-05	0.000275	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	1.18e-05	0.000274	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	1.16e-05	0.000268	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TH—polycystic ovary syndrome	1.12e-05	0.00026	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.12e-05	0.000259	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	1.12e-05	0.000259	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TH—polycystic ovary syndrome	1.11e-05	0.000258	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	1.09e-05	0.000253	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	1.08e-05	0.000251	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.03e-05	0.000239	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	1.03e-05	0.000238	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	1.02e-05	0.000236	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	9.99e-06	0.000231	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	9.98e-06	0.000231	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	9.63e-06	0.000223	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	9.51e-06	0.00022	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	9.26e-06	0.000214	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	9.18e-06	0.000212	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	9.14e-06	0.000211	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	9.1e-06	0.00021	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	9.01e-06	0.000208	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	8.75e-06	0.000202	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	8.67e-06	0.0002	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	8.63e-06	0.0002	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	8.5e-06	0.000196	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	8.4e-06	0.000194	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	8.29e-06	0.000192	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	8.22e-06	0.00019	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	7.73e-06	0.000179	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	7.66e-06	0.000177	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TH—polycystic ovary syndrome	7.35e-06	0.00017	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	7.15e-06	0.000165	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	6.81e-06	0.000158	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	6.72e-06	0.000155	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	6.72e-06	0.000155	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—INS—polycystic ovary syndrome	6.68e-06	0.000155	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	6.27e-06	0.000145	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	6.21e-06	0.000144	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	6.18e-06	0.000143	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—INS—polycystic ovary syndrome	6.15e-06	0.000142	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	6.13e-06	0.000142	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—INS—polycystic ovary syndrome	6.09e-06	0.000141	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	6e-06	0.000139	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	5.72e-06	0.000132	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	5.42e-06	0.000125	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	5.05e-06	0.000117	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	4.1e-06	9.47e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	4.04e-06	9.34e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—INS—polycystic ovary syndrome	4.02e-06	9.29e-05	CbGpPWpGaD
